Burning Rock Biotech Business Summary

Burning Rock Biotech Ltd (BNR) operates a precision oncology platform utilizing next-generation sequencing (NGS) to provide cancer therapy selection and early detection services. The company generates revenue through three primary segments: the Central Laboratory business, which sells diagnostic tests directly to individual patients; the In-Hospital business, which provides reagent kits and laboratory equipment facilitation to clinical institutions; and Pharma Research and Development Services, which earns fees and milestone payments from pharmaceutical partners for companion diagnostic (CDx) development and clinical trial support. As of early 2026, the company is strategically pivoting toward a decentralized in-hospital model and high-margin pharma collaborations, which saw nearly 70% year-over-year growth in 2025. Burning Rock competes directly with Guardant Health, Genetron Health, and Berry Genomics, positioning itself as a dominant leader in China’s NGS-based precision oncology market with an increasing footprint in international companion diagnostics. The leadership team is anchored by Founder, Chairman, and CEO Yusheng Han, who brings extensive life sciences and investment experience from his tenure at Northern Light Venture Capital and BioTek Instruments. Technical innovation is led by CTO Dr. Zhihong (Joe) Zhang, a former staff scientist at Illumina with a Ph.D. from Duke University, while financial operations are managed by CFO Leo Li. The company’s strategic direction is supported by a board featuring prominent venture capitalists, including Feng Deng, founder of Northern Light Venture Capital, and Gang Lu, a partner at Legend Star. Notable institutional backing includes Kynam Capital Management and Sumitomo Mitsui Trust Holdings, reflecting sustained investor confidence in the company’s transition toward a diversified, service-oriented oncology ecosystem.